The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.

摘要: Aim  The response to combined neoadjuvant therapy for advanced stage rectal adenocarcinoma is predictive of outcome. In addition both clinical and pathological features, the expression a variety molecules may provide another method identifying tumour responsiveness pre-operative therapy. aim this study was evaluate several markers in apoptotic pathway as well Cox-2 vascular endothelial growth factor (VEGF) determine their ability predict therapy. Method  total, 152 patients with were treated followed by resection. Paraffin-embedded sections obtained before after assessed immunohistochemical staining Cox-2, VEGF, p53, p21, p27, Bax, BCL-2 apoptosis protease-activating 1 (APAF-1). These stains correlated regression grade, complete T-downstaging surgical specimen. Clinical data also collected. Data analysed using χ2 Spearman’s correlation tests. Results  Pathological seen 24.5% patients. Amongst apoptosis-associated markers, only APAF-1 found be significantly associated grade (P < 0.001), (P < 0.031) (P < 0.004). On multivariate analysis, independently good grade. contrast, overexpression VEGF pretreatment biopsies related less (P < 0.003) likelihood (P < 0.03). Conclusion  Immunohistochemical evaluation initial biopsy specimens cancer APAF-1, adenocarcinoma. Those an expected limited considered other investigational protocols.